ResearchRSSToday
A study in Japan found that Hemlibra, a medicine used to treat acquired hemophilia A (a rare bleeding disorder that develops later in life), appears to be safe when used alongside other medications that suppress the immune system. Acquired hemophilia A is different from the hemophilia people are born with—it happens when the body mistakenly attacks its own clotting proteins. This is the first real-world evidence supporting Hemlibra's safety for this condition in actual patients.
WHY IT MATTERSIf you have acquired hemophilia A in Japan or are considering treatment options, this study suggests Hemlibra may be a safe addition to your treatment plan, though you should discuss this with your hematologist to see if it's right for your specific situation.
AdvocacyRSS3 days ago
A mother shares her personal story about raising two sons with severe hemophilia A, a bleeding disorder where the blood doesn't clot properly. She describes how she has had to stay strong and vigilant while caring for her children and managing the challenges that come with this lifelong condition.
WHY IT MATTERSPersonal stories from hemophilia caregivers help newly diagnosed families understand what to expect and show that others have navigated similar challenges successfully.
Drug approvalRSS4 days ago
Hympavzi is a new injection medicine approved in 2024 to help prevent bleeding in people with hemophilia. In the large study that led to its approval, the medicine worked well at stopping bleeds before they happened. When breakthrough bleeds did occur, doctors were able to treat them successfully using standard blood clotting medicines.
WHY IT MATTERSIf you have hemophilia, this news shows that Hympavzi can reduce bleeding episodes while still allowing doctors to treat any bleeds that do happen with familiar, proven treatments—meaning you don't have to choose between prevention and effective emergency care.
NewsRSS4 days ago
A person with hemophilia shares their experience deciding when and how to tell others about their condition. They describe how managing hemophilia—a bleeding disorder that requires regular factor VIII infusions every 48 hours—affects their daily life and social interactions. The article explores the personal challenge of balancing privacy with the need to explain absences or limitations caused by their treatment.
WHY IT MATTERSPeople with hemophilia often struggle with disclosure decisions that affect work, relationships, and social participation, and hearing from others navigating these choices can help patients develop their own communication strategies.
NewsRSS4 days ago
People with hemophilia need to work with their doctors to choose the best treatment plan. There are two main types of treatment: preventive medicine taken regularly to stop bleeding before it starts, and medicine taken only when bleeding happens. The right choice depends on each person's specific situation and needs.
WHY IT MATTERSUnderstanding prophylaxis versus on-demand treatment helps hemophilia patients and caregivers make informed decisions about which approach may reduce bleeding episodes and improve quality of life.
NewsRSS5 days ago
People with hemophilia experience pain that lasts long after bleeding episodes are treated. Joint damage from repeated bleeds can cause ongoing discomfort that affects daily life and quality of life. A patient named Thomas Graham shares his experience with how this lingering pain impacts his ability to do everyday activities.
WHY IT MATTERSMany hemophilia patients focus on stopping acute bleeds but don't realize that chronic pain and joint damage from past bleeds can significantly limit their quality of life even when bleeding is controlled.
AdvocacyRSS5 days ago
Thomas Graham shares his personal story about fighting with insurance companies to get the hemophilia treatment he needs. The article explains the barriers patients face when trying to access care and emphasizes that patients need to speak up for themselves. Insurance denials and delays are common problems for people with hemophilia, and knowing how to advocate can make a real difference.
WHY IT MATTERSHemophilia patients often face insurance denials or delays for clotting factor treatments, and learning advocacy strategies from patient experiences can help others navigate these barriers more effectively.
NewsRSS5 days ago
Hemophilia treatments work differently in different people's bodies. A doctor named G Shellye Horowitz explains that asking your doctor for pharmacokinetic testing can help make sure your hemophilia medicine is working the best way for your specific body. This test measures how your body processes the medication so doctors can adjust your dose if needed.
WHY IT MATTERSPharmacokinetic testing can personalize your hemophilia treatment plan, potentially improving how well your therapy controls bleeding and reducing the need for frequent dose adjustments.
🔴 BreakingDrug approvalRSSMay 15
Hympavzi, a new hemophilia treatment made by Pfizer, has been approved in Europe for more patients. The drug helps people with hemophilia A or B who have developed inhibitors—a complication where the body fights back against standard treatments. This approval expands who can use the medicine to help them bleed less and stay healthier.
WHY IT MATTERSEuropean hemophilia patients with inhibitors now have access to Hympavzi, a subcutaneous therapy that may reduce bleeding episodes and improve quality of life compared to traditional intravenous treatments.
ResearchRSSMay 12
A new study from Germany found that people with hemophilia who have advanced joint damage walk differently than others, mainly because their ankles don't move as well. To adapt to this limited ankle movement, their bodies develop new walking patterns that may use more energy and be less efficient. Understanding these changes could help doctors better support hemophilia patients in staying active.
WHY IT MATTERSIf you have hemophilia with joint damage, knowing that your altered walking pattern is a direct result of reduced ankle mobility could help you work with your doctor on targeted physical therapy or mobility interventions to improve efficiency and reduce fatigue.
Clinical trialRSSMay 8
A new medicine called denecimig (Mim8) was tested in a study called FRONTIER2 and worked better than current treatments at stopping bleeding episodes in people with hemophilia A. The medicine was given either once a month or once a week, and it worked well for both adults and teenagers 12 years and older, even for patients whose bodies have developed resistance to other treatments.
WHY IT MATTERSIf denecimig gains approval, hemophilia A patients—especially those with inhibitors who have limited treatment options—could switch to a once-monthly injection that reduces bleeds more effectively than their current preventive regimens.
NewsRSSMay 7
A parent shares a personal story about three important women in their life who have supported their two sons, Julian and Caeleb, who both have hemophilia A—a bleeding disorder where the blood doesn't clot properly. Each woman handled the diagnosis and care differently, showing different ways families can cope with and manage a rare disease.
WHY IT MATTERSThis article highlights how families living with hemophilia A navigate diagnosis and ongoing care, offering real-world perspectives that may help newly diagnosed families understand different approaches to managing a lifelong bleeding disorder.
PipelineRSSMay 5
The FDA has given special fast-track status to a new stem cell therapy being developed by Expression Therapeutics for hemophilia A, a bleeding disorder. This designation means the therapy can be reviewed faster than usual. The therapy is designed to be a one-time treatment that could provide lasting relief from hemophilia A symptoms.
WHY IT MATTERSIf successful, this one-time stem cell therapy could eliminate the need for regular blood clotting factor infusions that hemophilia A patients currently require multiple times per week.
ResearchRSSMay 1
A new study found that many women who carry hemophilia gene mutations are not getting proper medical care, even though they live in countries with good healthcare systems. These women often don't know they carry the mutation and aren't included in official patient lists. The main problem is that they can't easily access genetic testing to find out if they have the mutation.
WHY IT MATTERSWomen with hemophilia mutations may experience bleeding problems and need specialized care, but without diagnosis and medical attention, they won't know to seek treatment or get proper support for their health.
Clinical trialRSSApr 28
Researchers tested a new medicine called bemiltenase alfa that helps control bleeding in people with hemophilia A and B. These patients had developed resistance to standard treatments, making their bleeding harder to manage. Early trial results show this new medicine may help them control bleeding when it happens.
WHY IT MATTERSFor hemophilia patients who have developed inhibitors (antibodies that block standard treatments), bemiltenase alfa offers a potential new option for on-demand bleeding control when current therapies no longer work effectively.
Clinical trialRSSApr 24
A new treatment called Roctavian was given as a single injection to men with severe hemophilia A (a bleeding disorder). Seven years later, most patients had fewer bleeding episodes and needed less preventive medicine. This suggests the treatment's benefits can last for many years.
WHY IT MATTERSIf you have severe hemophilia A, Roctavian could mean switching from frequent infusions or injections to a single treatment that protects you from bleeds for years.
AdvocacyRSSApr 24
A person recently attended the Hemophilia Federation of America's annual symposium in New Orleans and shared their positive experience meeting others in the hemophilia community. The event inspired reflection on both current progress in treating hemophilia and the difficult history the community has faced. The author expressed gratitude for being included and highlighted the importance of gathering with others who understand the challenges of living with a bleeding disorder.
WHY IT MATTERSCommunity events like the HFA Symposium provide hemophilia patients and caregivers with opportunities to connect with others, learn about new treatments, and access support networks that can improve quality of life and treatment decisions.